Gemin X Biotechnologies Inc.

Gemin X Biotechnologies Inc. specializes in the discovery and development of novel cancer therapeutics. The company's expertise is in apoptosis, or harnessing the body's natural defense against injured or damaged cells. Using its proprietary discovery platform, Gemin X has identified a family of small molecules that effectively inhibit the Bcl-2 protein, a validated drug target implicated in B cell lymphoma, breast, lung, prostate and colorectal cancer. Additionally, the company has programs dedicated to the identification of novel cancer targets and therapeutics; discovering small molecules that promote apoptosis in cells infected with latent viruses; and finding compounds that act against p53 independent chemo-resistant ( www.geminx.com )